Research Alliance Corporation III — Form 10-Q Summary
Reporting period: Quarter ended September 30, 2026; the company was incorporated February 19, 2026. Financial statements are unaudited. As a blank-check SPAC, it had not begun operating activities or generated operating revenue.
Financial results and position
| Metric | Q3 2026 | Inception through September 30, 2026 |
|---|---|---|
| Operating revenue | None | None |
| General, formation and administrative expenses | $977,793 | $1,227,460 |
| Interest income on trust investments | $714,805 | $953,273 |
| Net loss | $1,950,387 | $1,961,586 |
| Basic and diluted loss per share | $0.21 | $0.33 |
- At September 30, cash outside the trust was $183,405; current assets were $312,054 and working capital deficit was $2,597,399.
- Trust investments were $75,953,273, held in U.S. Treasury securities. Redeemable public shares were recorded at $10.13 per share.
- Total liabilities were $6,846,852, including a $1,687,399 backstop liability and $2,250,000 deferred underwriting fee payable. The company reported no long-term debt; the deferred fee is payable only if a business combination closes.
- From inception through quarter-end, operating cash use was $1,047,844; IPO proceeds of $75 million were deposited in trust. Financing activities provided $76,231,249, and ending cash was $183,405.
- No prior-year comparable results are presented because the company began in 2026. Q3 figures are therefore not comparable to a prior-year quarter.
Business combination, outlook and risks
- On July 26, 2026, the company agreed to combine with OHB Pediatrics Ltd. (OHBP). The proposed transaction would domesticate the SPAC as a Delaware corporation named Oak Hill Bio, Inc. Shareholder approval and other closing conditions remain outstanding.
- The SEC declared the transaction registration statement effective November 4, 2026; the shareholder meeting was scheduled for November 24. Management expected closing in Q4 2026, but completion is not assured.
- Proposed transaction financing includes a $55 million PIPE and a backstop commitment of up to $75 million, subject to conditions and adjusted for shares not redeemed. RA Capital funds also agreed to provide OHBP $45 million under SAFEs bearing 8% interest; these are OHBP financing arrangements, not RACC debt reported at quarter-end.
- Management disclosed substantial doubt about the company’s ability to continue as a going concern because it lacks resources to sustain operations for one year from issuance. It expects to rely on potential sponsor or affiliate loans, which are not assured. No working capital loans were outstanding at September 30; in November, RACC borrowed $146,250 under a new sponsor loan agreement, with up to $3 million potentially convertible at the sponsor’s option.
- The backstop liability is measured using significant unobservable inputs. Its initial $2,176,798 fair value and subsequent $489,399 gain on remeasurement affected earnings.
- Disclosure controls were found ineffective due to a material weakness in accounting for accounts payable and accrued expenses, including classification between offering costs and operating expenses. Remediation steps began but were not complete at quarter-end.
- Management noted that geopolitical instability and global market volatility could adversely affect the company or its ability to complete the transaction; the impact was not readily determinable. The filing reports no material litigation and no long-term lease obligations.
Most important facts to verify
- Whether shareholders approve the OHBP transaction and all other closing conditions, including Nasdaq listing and financing conditions, are satisfied.
- Actual redemptions, backstop funding, PIPE proceeds and final transaction equity value and dilution.
- RACC’s near-term ability to fund transaction expenses, given its low unrestricted cash, working capital deficit and going-concern disclosure; also verify terms and use of the November sponsor loan.
- Progress in remediating the material weakness and whether subsequent reporting reflects reliable expense and offering-cost classification.
- The cover page checks “No” for filing all required Exchange Act reports during the preceding 12 months; verify the reason and any reporting-compliance implications.